In an article published in Nature on Feb. 15, 2017, researchers, including principal investigators from the Montreal Neurological Institute’s McConnell Brain Imaging Centre (BIC), used magnetic resonance imaging (MRI) to predict the development of autism in babies.
Montreal, Quebec and Vancouver, British Columbia – Working together to accelerate research into neurological diseases, three leading players in Canada’s health sciences sector are joining forces in a unique multi-million dollar partnership to create a novel drug development platform that will help advance new therapeutics for some of the most debilitating conditions such as amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, and Parkinson’s disease.
A foray into plant biology led one researcher to discover that a natural molecule can repair axons, the thread-like projections that carry electrical signals between cells. Axonal damage is the major culprit underlying disability in conditions such as spinal cord injury and stroke.
Research and clinical care complement each other at The Neuro
February 28th was Rare Diseases Day, an opportunity to recognize a class of disease that is often overlooked. In the past five years, the Montreal Neurological Institute and Hospital (The Neuro) has made the study and treatment of rare diseases a major priority, hiring new specialists and support staff and coordinating activity under a new research group.
In September 2016, the federal government made an unparalleled investment in research and innovation, announcing $84 million in funding over seven years for McGill’s Healthy Brains for Healthy Lives initiative, as part of the Canada First Research Excellence Fund (CFREF) program. Following this announcement, a committee for the selection of the HBHL Managing Director engaged in an extensive search and interview process. The Chair of the Selection Committee, Vice-Principal Rosie Goldstein, is now pleased to announce the appointment of Dr.
In September 2016, the federal government made an unparalleled investment in research and innovation, announcing $84 million in funding over seven years for McGill’s Healthy Brains for Healthy Lives initiative, as part of the Canada First Research Excellence Fund (CFREF) program. Following this announcement, a committee for the selection of the HBHL Managing Director engaged in an extensive search and interview process. The Chair of the Selection Committee, Vice-Principal Rosie Goldstein, is now pleased to announce the appointment of Dr.
CQDM and Brain Canada join forces again in the funding of two new research projects to address unmet needs in brain research
CQDM and Brain Canada are proud to announce the funding of two new multi-disciplinary and multi-institutional research projects under the second edition of their Focus on Brain strategic initiative. The partners will award a total of $3M to two research teams to develop cutting-edge tools, technologies and platforms designed to accelerate the discovery of new drugs for brain and nervous system disorders.
An all-star lineup of experts in the fields of sports and neurology will share a stage on Jan. 27 to discuss concussions, a serious injury that has only recently been getting the attention it deserves.
The 85th Congrès annuel de l’Association francophone pour le savoir (Acfas) may be five months away, but McGill is already busy getting ready to host what is the largest French-language interdisciplinary conference in the world.
Researchers urged not to miss Nov. 1 deadline for colloquia proposals.
Have you ever met someone who just wasn’t into music? They may have a condition called specific musical anhedonia, which affects three-to-five per cent of the population.
Researchers at the University of Barcelona and the Montreal Neurological Institute and Hospital of Ď㽶ĘÓƵ have discovered that people with this condition showed reduced functional connectivity between cortical regions responsible for processing sound and subcortical regions related to reward.
Drug shown to reduce new attacks/symptom progression in some patients
In separate clinical trials, a drug called ocrelizumab has been shown to reduce new attacks in patients with relapsing remitting multiple sclerosis (MS), and new symptom progression in primary progressive MS.
Research Seminar - 'Doing PAR in Troubled Times' with Dr. Steven Jordan
Study tracks patients to better understand effects and possible treatments
December 1 is World AIDS Day, a time to raise awareness about a disease that has afflicted 70 million people worldwide, 35 million of whom have died as a result.
Researchers have linked a debilitating neurological disease in children to mutations in a gene that regulates neuronal development through control of protein movement within neuronal cells.
